Eli Lilly and Company (NYSE: LLY) was founded in 1876 and has grown into one of the world's leading biopharmaceutical companies by investing on sustained research and development, and capitalizing on new growth opportunities. The company operates five business segments - Bio-Medicines, Diabetes, Elanco Animal Health, Emerging Markets, and Oncology - and sells its products in over 120 countries. Eli Lilly employs over 8,000 individuals solely in its R&D department, and spends approximately $91 million each week on the research and development of new drugs. In FY 2014, Eli Lilly had net sales of $19.62 billion and net income of $2.39 billion. ...

This document is currently available only to members of our Options subscription.
For more information about our subscriptions, please visit our products page.
Outdated document.
The document was written more than 6 months ago. Information may be outdated.